We will discover the future after next month's meeting when the big stockholder vote is revealed. Leaving Delaware will save the company tons of paper money. Moving to Nevada will allow them more time to grow the Helomics division, the area with the most potential. Until making money is constant, saving money becomes essential. Moving allows POAI more time to make deals with companies who could benefit from their tumor research. Also, perhaps the company will be bought as a snack for one of the larger research companies. If either positive scenario works those of us holding shares may get our money back. If neither work shares may go to zero. Just my take. Thoughts?
News 
Market Data 
Discover 
